Arkolith/Insider Trading/ADAP/Form 4

Rawcliffe Adrian

Chief Executive Officer, DirectorAdaptimmune Therapeutics PLC (ADAP) · full profile →Form 4 · filed Jan 17, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 15, 2024Grant(A)7.6M—$07.6M
Jan 15, 2024Grant(A)1.7M—$01.7M

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-004520) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML